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Despite the fact that multiple sclerosis (MS) and Alzheimer’s disease (AD) share common neuroimmunological
features, interferon beta 1a (IFNβ1a), the well-established treatment for the prevention of disease progression and
cognitive decline in MS patients, has never been used in AD. We evaluated the safety and efficacy of IFNβ1a in
subjects affected by mild-to-moderate AD in a double-blind, randomized, placebo-controlled, multicenter pilot
study. Forty-two early Alzheimer’s patients were randomized to receive either a 22 mcg subcutaneous injection of
IFNβ1a or placebo three times per week. A treatment period of 28 weeks was followed by 24 weeks of observation.
IFNβ1a was well tolerated and adverse events were infrequent and mild to moderate. Although not statistically
significant, a reduction in disease progression during follow-up was measured in IFNβ1a-treated patients by the
Alzheimer’s Disease Assessment Scale cognitive subscale. Interestingly, the treatment group showed significant
improvements in the Instrumental Activities of Daily Living and Physical Self-maintenance Scale. This study suggests
that IFNβ1a is safe and well tolerated in early AD patients, and its possible beneficial role should be further
investigated in larger studies.
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Alzheimer disease (AD) is one of the major health prob-
lems affecting the aging world [1,2]. The disease is char-
acterized by the accumulation in the brain of abnormally
folded protein fragments (amyloid beta peptide, Aβ, and
tau protein) forming amyloid plaques and neuronal tan-
gles [3] whose appearance is associated with low-grade
inflammation, advancing neuronal loss, and progressive
cognitive decline. Plaque-associated microglia are able to
respond to various stimuli by increasing their expression
of histocompatibility complex (MHC) class II antigens
and complement receptors as well as proinflammatory
cytokines such as IL1β, IL6, and tumor necrosis factor-
alpha (TNF-α) [4-6]. In addition, vascular lesions affecting
the cerebral endothelium can alter the blood–brain barrier
(BBB), especially in AD patients with predisposing vascu-
lar abnormalities such as hypertension, cardiovascular dis-
ease and diabetes [7]. Similarly, in multiple sclerosis (MS),* Correspondence: luigi.grimaldi@hsr.it
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unless otherwise stated.an immune-mediated disease of the brain characterized by
inflammatory-mediated degenerative processes affecting
the white matter of the central nervous system and caus-
ing demyelination of neuronal axons, microglia and astro-
cytes are activated and express elevated MHC class II
antigen expression, as well as intercellular adhesion mole-
cules (ICAM-1) and proinflammatory cytokines including
IL1β, IL6 and TNF-α [8-11].
Interferon beta (IFNβ) was first tested for its antiviral
property for the possible involvement of viral infections
in the pathogenesis of MS and is now widely used for its
immunomodulatory and antiproliferative properties in
the treatment of this demyelinating disease [12]. Some
of the mechanism of action of IFNβ include a shift from
pro- to anti-inflammatory cytokines production [13,14];
inhibition of T-cell activation, blockage of production of
oxygen free radicals by mononuclear phagocytes, and re-
duced expression of MHC II [15]; a protective role against
BBB disruption by reducing the activity of metallopro-
teases and thereby preventing T-cells infiltration in the
CNS [16]; a neuroprotective effect on retinal ganglion cellsl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Adverse events recorded in Placebo-and IFNβ
1-treated subjects
Adverse event Placebo IFN β 1a Total
Severity Mild Moderate Mild Moderate
Articular pain 2a 0 0 0 2
Fever 0 0 1a 0 1
High cholesterol 0 0 3c 0 3
High level of ALT and AST 0 1b 0 1b 2
High pseudocholinesterase 1c 0 1c 1c 3
High triglycerides 0 0 0 1c 1
High TSH 0 1c 0 0 1
Low blood pressure 1c 0 0 0 1
Repolarization ventricular
anomaly
0 0 1c 0 1
Right ear buzzing 1b 0 0 0 1
Flu-like syndrome 1c 0 0 0 1
TOTAL 6 2 6 3 17
The number of adverse events in the two treatment arms is reported in details
subdivided by severity degree. The relation to drug administration is shown as
follows: aprobably related; bunlikely related; cunrelated. ALT, alanine
aminotransferase; AST, aspartate aminotransferase; TSH, thyroid
stimulating hormone.
Table 2 Demographics and physical characteristics at
baseline
Characteristic Placeboa Interferon beta 1aa P value
Age at informed
consent (yrs)
64.57 ± 6.4 63.0 ± 9.07 0.57
Height (cm) 165.11 ± 7.52 163.0 ± 9.01 0.42
Weight (kg) 71.59 ± 9.92 68.17 ± 10.04 0.27
Systolic pressure
(mmHg)
131.05 ± 7.56 164.74 ± 18.26 0.31
Diastolic pressure
(mmHg)
79.47 ± 6.64 116.26 ± 19.2. 0.26
Pulse rate (bpm) 70.94 ± 11.88 71.56 ± 6.97 0.86








14 (yes); 4 (no) 14 (yes); 8 (no) 0.94
aValues are expressed as means ± SD. bSex values are reported as
absolute values.
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factors by endothelial cells [17,18].
Interestingly, IFNβ1a significantly prevented cognitive
decline in a large cohort of patients with MS, thus sug-
gesting that modulation of neuroinflammatory pathways
might prevent cognitive decline in humans [19].
At present, no effective treatment is available to stop
disease progression in AD. Several immunomodulating
strategies in experimental animal models and human clin-
ical trials have recently attempted to alter the immuno-
logical pathways underlying the pathological changes seen
in AD patients with conflicting results [20,21]. Based on
the similarity of some of the immunopathological path-
ways shared by AD and MS, the similar alteration of the
BBB, as well as the positive effects on cognition in MS pa-
tients treated with IFNβ1a, we evaluated in a proof-of-
concept pilot trial the safety and possible efficacy of sub-
cutaneous (s.c.) low dose IFNβ1a in patients diagnosed
with early mild AD.
Methods
Study design
This double-blinded, randomized, placebo-controlled, mul-
ticenter pilot study (clinicaltrials.gov Identifier: NCT010
75763) was conducted according to the declaration of
Helsinki. After receiving protocol approval from the
Local Ethical Committee, we obtained informed con-
sent from all patients. Patients were considered eligible if
they were between 50 and 75 years of age, were diagnosed
with AD according to the Diagnostic and Statistical Man-
ual of Mental Disorders, 4th edition (DSM-IV), had a
Mini Mental State Examination (MMSE) score between
20 and 26, and were supervised by a caregiver. Exclusion
criteria included: use, in the previous 3 months, of statins,
nonsteroidal anti-inflammatory drugs, steroids, or cholin-
esterase inhibitors that could modify the course of the dis-
ease; a Modified Hachinski Ischemic Score ≤4; inability to
undergo neuropsychological evaluation; significant liver,
thyroid or hematological dysfunctions; severe cardiac dis-
ease, or epilepsy; a history of depression unresponsive to
medication; past medical history of suicidal ideation;
current use of hypnotic, anxiolytic, antidepressant, anti-
psychotic or anticholinergic drugs; and, finally, any known
allergic reactions to interferons or other components of
the study drug.
A total of 47 patients were screened at 5 AD centers,
and 42 patients were enrolled between December 2004
and May 2007. Patients’ baseline characteristics are de-
tailed in Tables 1 and 2.
Subjects were randomized into two groups: one (n = 23)
receiving IFNβ1a (Rebif®, Merck Serono S.A. - Geneva,
Switzerland), 22 mcg subcutaneous injection (s.c.), three
times per week; the other (n = 19) receiving placebo
with the same schedule and route of administration. Thetreatment period was 28 weeks and patients were followed
for up to 52 weeks (Figure 1). Outcome measures were
monitored at baseline, week 28, and week 52. The primary
efficacy evaluation was the Alzheimer’s Disease Assess-
ment Scale cognitive subscale (ADAS-Cog). Secondary
efficacy evaluations included Global Deterioration Scale
(Global DS), Clinician Interview Based Impression of
Change (CIBIC-plus), Mini-Mental State Examination
(MMSE), ADAS non-cognitive subscale (ADAS-Non-
Cog), Instrumental Activities of Daily Living (IADL),
Trial flowchart
Patients assessed for eligibility 
(n=47)
Excluded  (n=5)
♦ Declined to participate (n=3)
♦ Other reasons (n=2)
Analysed  (n=19)
♦ Excluded from analysis:









Allocated to placebo(n=19) 
Analysed  (n=15)
♦  Excluded from analysis 
Lost to follow-up (n=1)
Lack of efficacy (n=1)
Consent withdrawn (n=2)
Randomized (n=42)
Figure 1 Trial flowchart giving details on the number of patients screened and taking part in each phase of the trial.
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Depression Scale (GDS). At each routine visit serum
chemistry, hematological, and urine abnormalities were
evaluated, and physical and neurological examinations
were performed.
Statistical analysis
Primary and secondary endpoints were assessed by arm-
descriptive analysis (mean, median, SD, range) of measured
values at each time point and related changes over time. In
addition, a preliminary assessment of normality was
performed for each continuous scale. Mean differences
with screening/baseline was tested using repeated
measures T-test and ANOVA, as appropriate. The other
secondary outcome measures were assessed at screening/
baseline and at week 12, week 28 and week 52 (Mini Men-
tal Status Examination (MMSE), ADAS, non-cognitive
subscale (ADAS-NonCog) or at week 28 and 52 (Instru-
mental Activities of Daily Living (IADL), Physical Self-
Maintenance Scale (PSMS), Clinician’s Interview Based
Impression of Change (CIBIC-PLUS), Geriatric depression
scale (GDS), and Global Deterioration Scale). Meandifferences between follow-up and baseline of nonparame-
trically distributed variables (all test with the exception
of GDS) were assessed using Wilcoxon scores and the
Kruskal-Wallis test, while arm-specific differences were
analyzed by Wilcoxon signed-rank test. Qualitative vari-
ables (for example, CIBIC-PLUS) were compared as




The study drug was well tolerated and adverse events
were reported in 4/42 (9 %) of the subjects, with no sig-
nificant differences in the two arms. None of the adverse
events were serious or resulted in death or early termin-
ation of study. The total number of adverse events was
17, 12 of which were mild and 5 were moderate. More-
over, only three of the adverse events were related to
drug administration (Table 1). Ten events had resolved
by the end of the study.
No significant changes in vital signs, or hematological or
urinalysis parameters were reported; although, a mild
Table 3 Neuropsychological tests values at baseline
Test Placeboa Interferon beta 1aa P value
ADAS-Cogb 19.81 ± 6.14 18.34 ± 7.85 0.34
MMSEc 22.93 ± 1.78 23.45 ± 2.13 0.41
ADAS-NonCogd 6.06 ± 5.0 4.36 ± 4.12 0.30
PSMSe 6.4 ± 0.91 6.42 ± 1.01 0.98
GDSf 10.66 ± 6.53 10.10 ± 6.12 0.79
Global DSg 2.86 ± 0.74 3.0 ± 0.47 0.50
IADLh 6.2 ± 1.56 6.1 ± 1.44 0.68
aValues are expressed as means ± SD. bADAS-cog, Alzheimer’s Disease
Assessment Scale-cognitive subscale; cMMSE, Mini Mental State Examination;
dADAS-Non-Cog, Alzheimer’s Disease Assessment Scale-Non-Cognitive Section;
ePSMS, Physical Self-Maintenance Scale; fGDS, Geriatric Depression Scale;
Global, gGlobal Deterioration Scale (DS) for Assessment of Primary Degenerative
Dementia; hIADL, Instrumental Activities of Daily Living Scale.
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group but not in the placebo arm (3/19 versus 0/15,
P = < 0.05).Efficacy
Patients in the placebo and study drug randomized
groups shared the same baseline characteristics with no
significant differences, as shown in Table 2. Similarly,
the baseline means scores of all parameters measured in
the study did not differ in the two arms, confirming that
the randomization did not generate any bias in the
protocol, as detailed in Table 3.Table 4 Analysis of change (delta values) of outcomes at stud
Test Treatment Delta value T1b versus T2c
ADAS-Coge IFNβ 1a 0.144 ± 1.16
Placebo 2.25 ± 1.05
MMSEf IFNβ 1a 0.78 ± 0.52
Placebo 0.73 ± 0.98
ADAS-NonCogg IFNβ 1a −0.26 ± 0.53
Placebo 0.86 ± 0.75
PSMSh IFNβ 1a 0.31 ± 0.23
Placebo 0.6 ± 0.6
GDSi IFNβ 1a 0.42 ± 0.94
Placebo 2.0 ± 1.34
Global DSj IFNβ 1a −0.05 ± 0.17
Placebo −0.13 ± 0.13
IADLk IFNβ 1a 0.26 ± 0.34
Placebo 0.6 ± 0.36
aValues are shown as means ± SEM; Negative change indicates worsening of condit
bT1 = baseline (week 0); cT2 = end of treatment (week 28); dT3 = follow-up (week 54
Mini Mental State Examination; gADAS-Non-Cog, Alzheimer’s Disease Assessment Sc
Geriatric Depression Scale; Global, jGlobal Deterioration Scale (DS) for Assessment o
Living Scale.The primary outcome measure, ADAS-Cog, showed
no significant progression of AD during the 28-week
treatment period, while a worsening was observed dur-
ing follow-up, as shown by the delta values of ADAS-
Cog score when comparing the different time points of
the trial (Table 4). However, no significant differences of
overall efficacy were observed between placebo and
treatment group.
The same trend was observed for MMSE, and ADAS-
NonCog scores, thus indicating a positive effect of treat-
ment on the disease decline but without significant
differences between the two treatments arms (Table 4).
Interestingly, there was a significant improvement of
both PSMS and IADL scores in the IFNβ1a group at
follow-up compared with both baseline and end of treat-
ment. The Global Deterioration Scale showed a modest
decline in patients of the two arms during the treatment
period and between baseline and follow-up. However, no
significant differences were observed. Similarly, CIBIC-
plus, measured at 28 and 52 weeks, did not show any dif-
ferences between arms (data not shown). Conversely, the
GDS score significantly improved in the placebo group,
overall and during follow up (Table 4).
Discussion
New treatments for MS are expected to become avail-
able within the next 2 years [22]. Conversely, AD is still
lacking a convincing strategy to halt the progressive
decline of cognitive function associated with protein ac-
cumulation within the brain. The now well-establishedy time pointsa
Delta value T2 versus T3d Delta value T1 versus T3
−2.17 ± 1.01 (p = 0.031) −2.02 ± 1.58
−2.78 ± .1.02 −0.52 ± 1.86
−1.81 ± 0.69 (p = 0.037) −1.02 ± 1.03
−1.68 ± 0.76 −0.95 ± 1.0
−0.84 ± 0.35 −1.10 ± 0.65
−2.0 ± 1.099 −1.13 ± 1.26
1.05 ± 0.66 (p = 0.0459) 1.36 ± 0.76 (p = 0.025)
−0.13 ± 0.29 0.46 ± 0.33
−1.10 ± 0.79 −0.68 ± 1.35
1.57 ± 0.83 (p = 0.0418) 3.57 ± 1.24 (p = 0.009)
−0.21 ± 0.12 −0.26 ± 0.18
−0.2 ± 0.10 −0.33 ± 0.15
0.94 ± 0.37 (p = 0.0306) 1.20 ± 0.59 (p = 0.041)
−0.06 ± 0.18 0.53 ± 0.36
ion. In brackets are reported p values (by arm) when statistically significant.
). eADAS-cog, Alzheimer’s Disease Assessment Scale-cognitive subscale; fMMSE,
ale-Non-Cognitive Section; hPSMS, Physical Self-Maintenance Scale; iGDS,
f Primary Degenerative Dementia; kIADL, Instrumental Activities of Daily
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genesis of plaque formation offers an interesting target
for treatment. At present, numerous attempts to alter
the inflammatory processes in AD have been performed
using different anti-inflammatory drugs [20,21].
Although IFNβ1a has a well-established positive safety
profile in the young adult (the typical MS population),
little is known in older patients (typical AD population).
We assessed the safety of IFNβ1a for the treatment of
patients affected by mild AD and found that this drug
was well tolerated. The number of adverse events re-
ported was low and their severity was mild to moderate
and comparable between the two arms of the study.
Our study was clearly not powered to demonstrate ef-
ficacy. However, although no statistically significant dif-
ference between the IFNβ1a and the placebo groups was
reported for the major outcome measure of the study,
the ADAS-Cog score, the improvement noted in the
IFNβ1a treatment group was maintained during the
24-week follow-up period. Similarly, improvement in the
ADAS-NonCog score was maintained. Importantly, sig-
nificant improvements in the IADL and in the PSMS
scores, extending to the follow-up phase, were observed
in the IFNβ1a treatment group.
These results show that, although treatment with
IFNβ1a did not perform better than placebo during the
treatment period, a slower decline could be observed in
the active drug group during the follow-up period, indi-
cating a prolonged protective effect of IFNβ1a.
Paradoxically, but not surprisingly, we found that the
placebo had an antidepressant effect, as shown by the
significant improvement in the Geriatric Depression
Scale, suggesting that this effect may have been respon-
sible for improvement in the placebo group during the
6 months of treatment. Mood elevation engendered by
the placebo may have counterbalanced any positive cog-
nitive outcome of the active drug, which is well known
to produce a transient mood decline during the first
months of treatment [23].
Interestingly, a cholesterol lowering trend was observed
in IFNβ1a treated patients, indicating a possible additional
mechanism for its efficacy since cholesterol might play a
role in the pathogenesis of AD, and cholesterol lowering
agents, such as statins, have been tested as treatment for
AD [24,25]. Recently, Weinstock-Gutmann et al. [26],
reported that in early MS patients, higher levels of low
density lipoprotein cholesterol (LDL-C) and total chol-
esterol (TC) are associated with increased inflammation
(by MRI evaluation) in subjects affected by a clinically
isolated syndrome and treated with intramuscular injec-
tion of IFNβ1a.
In conclusion, our study demonstrates the tolerability,
short-term safety and feasibility of using IFNβ1a in treat-
ment of older patients at risk for AD-related cognitivedecline. Our findings suggest that the strategy used here
should be further investigated in larger studies targeting
subjects in early stage disease where inflammatory-
mediated facilitation of misfolded-protein accumulation
is more likely to occur.
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